A Trial Evaluating TG4050 in Ovarian Carcinoma.

Exclusion Criteria

• •1. Patient having received any cancer immunotherapy including cancer vaccines, any antibody/drug targeting T cell co-regulatory proteins such as anti-Programmed cell death 1 (anti-PD1), anti-Programmed death-ligand 1 (anti-PDL1) or anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTL4)
• •2. Patients with other active malignancy ≤ 3 years prior to registration except non-melanoma skin cancer, stage 0 in situ carcinoma.
• •3. Patient post-organ transplantation, including allogeneic stem cell or bone marrow transplantation.
• •4. Known history of positive testing for Human Immunodeficiency Virus (HIV) or known AIDS (Acquired Immune Deficiency Syndrome).
• •5. Any known allergy or reaction to eggs or attributed to compounds of similar chemical or biological composition to therapeutic vaccines/immunotherapeutic products.
• •6. Acute or chronic infection with hepatitis C Virus (HCV) or Hepatitis B Virus (HBV).
• •7. Major surgery within 4 weeks of treatment start.
• •8. Treatment with another investigation agent within 30 days prior to TG4050 treatment initiation.
• •9. Patients under chronic treatment with systemic corticosteroids or other immunosuppressive drugs . Steroids with no or minimal systemic effect (topical, inhalation) are allowed.
• •10. Use of live vaccine for the prevention of infectious diseases during the four-week period prior to TG4050 treatment initiation planned date. Furthermore, patients should not receive any live vaccine during the period of study treatment administration.
• •11. Uncontrolled intercurrent illness.